Page last updated: 2024-12-10

n-oleoylethanolamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-oleoylethanolamine: ceramidase inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

oleoyl ethanolamide : An N-(long-chain-acyl)ethanolamine that is the ethanolamide of oleic acid. The monounsaturated analogue of the endocannabinoid anandamide. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5283454
CHEMBL ID280065
CHEBI ID71466
SCHEMBL ID177713
MeSH IDM0104159

Synonyms (102)

Synonym
MLS002153155
smr001230650
gtpl2661
AKOS015839895
EU-0100942
n-oleoylethanolamine, ~98% (tlc)
n-oleoylethanolamine
oleoyl monoethanolamide
einecs 203-884-8
9-octadecenamide, n-(2-hydroxyethyl)-
monoethanolamine oleic acid amide
oleamide mea
9-octadecenamide, n-(2-hydroxyethyl)-, (z)-
n-(2-hydroxyethyl)-9-octadecenamide
9-octadecenamide, n-(2-hydroxyethyl)-, (9z)-
LOPAC0_000942
NCGC00015761-01
lopac-o-0383
tocris-1484
NCGC00025182-01
SPECTRUM5_002037
oleic monoethanolamide
111-58-0
oleylethanolamide
n-(2-hydroxyethyl)oleamide
n-(cis-9-octadecenoyl) ethanolamine
LMFA08040015
n-(9z-octadecenoyl)-ethanolamine
n-oleoyl ethanolamine
n-oleoyl ethanolamide
n-(hydroxyethyl) oleamide
NCGC00025182-06
NCGC00025182-04
NCGC00025182-02
NCGC00025182-05
NCGC00015761-03
nae 18:1
n-(hydroxyethyl)oleamide
O 0383
NCGC00015761-07
bdbm29080
chembl280065 ,
oleoylethanolamide (oea)
oleoyl ethanolamide
chebi:71466 ,
oleoylethanolamide
n-(2-hydroxyethyl)octadec-9-enamide
A802386
(z)-n-(2-hydroxyethyl)octadec-9-enamide;oleoylethanolamide
HMS3262N06
(z)-n-(2-hydroxyethyl)octadec-9-enamide
oea ,
n-oleoylethanolamide
1hi5j9n8e6 ,
unii-1hi5j9n8e6
CCG-205023
HMS2233E21
NCGC00015761-06
NCGC00015761-05
NCGC00015761-04
NCGC00015761-02
LP00942
9-octadecenamide, n-(2-hydroxyethyl)-, z
oleamide mea [inci]
oleylethanolamide [who-dd]
(9z)-n-(2-hydroxyethyl)octadec-9-enamide
n-(9z-octadecenoyl) ethanolamine
oleoyl 1-ethanolamide
SCHEMBL177713
tox21_500942
NCGC00261627-01
DTXSID1044516
oleic acid ethanolamide
(9z)-n-(2-hydroxyethyl)-9-octadecenamide
C20792
n-(2-hydroxyethyl)-9z-octadecenamide
W-109412
HMS3649J05
mfcd00045972
oleic acid monoethanolamide
n-oleoyl ethanolamine, oleoyl monoethanolamide, oleoylethanolamide
nae(18:1)
SR-01000076041-1
SR-01000076041-3
sr-01000076041
CS-0028847
HY-107542
c18:1 anandamide, 9z-octadecenoylethanolamide, powder
HMS3676D21
n-oleoyl-2-aminoethanol
AS-15152
SR-01000076041-8
HMS3412D21
Q7086404
SDCCGSBI-0050916.P002
NCGC00015761-12
oleic acid monoethanolamiden-oleoylethanolamide
D82195
olemsartan medoximil
n-oleoylethanolamide; oleamide mea; oleic acid monoethanolamide
5YM ,
O0345

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"Cell membrane permeability is an important determinant for oral absorption and bioavailability of a drug molecule."( Highly predictive and interpretable models for PAMPA permeability.
Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR, 2017
)
0.46

Dosage Studied

ExcerptRelevanceReference
" The in vitro study showed that 1 microM OEA exerted a significantly neuroprotective effect on cultured nigral dopamine neurons, effects following U-shaped dose-response curves."( Oleoylethanolamide exerts partial and dose-dependent neuroprotection of substantia nigra dopamine neurons.
Bermudez-Silva, FJ; Fernandez-Espejo, E; Galan-Rodriguez, B; Gonzalez-Aparicio, R; Maldonado, R; Robledo, P; Rodriguez de Fonseca, F; Suarez, J, 2009
)
0.35
"Effects of pre-treatment with a single dose, versus 4 day repeated dosing with the selective FAAH inhibitor, URB597 (i."( Lack of effect of chronic pre-treatment with the FAAH inhibitor URB597 on inflammatory pain behaviour: evidence for plastic changes in the endocannabinoid system.
Alexander, SP; Barrett, DA; Bennett, AJ; Burston, J; Chapman, V; Kendall, DA; Norris, LM; Okine, BN; Patel, A; Woodhams, S, 2012
)
0.38
"0mg/kg, but at a lower dosage (0."( Decreased anxiety in juvenile rats following exposure to low levels of chlorpyrifos during development.
Armstrong, NH; Buchanan, AT; Carr, RL; Eells, JB; Mohammed, AN; Nail, CA; Ross, MK, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
PPARalpha agonistA PPAR modulator which activates the peroxisome proliferator-activated receptor-alpha.
EC 3.5.1.23 (ceramidase) inhibitorAn EC 3.5.1.* (non-peptide linear amide C-N hydrolase) inhibitor that interferes with the action of ceramidase (EC 3.5.1.23).
geroprotectorAny compound that supports healthy aging, slows the biological aging process, or extends lifespan.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
N-(long-chain-acyl)ethanolamineAny N-acylethanolamine in which the acyl group has a chain length of C12 or greater.
endocannabinoidA class of cannabinoids present in mammalian biological fluids and tissues that activate cannabinoid receptors.
N-acylethanolamine 18:1An N-acylethanolamine in which the acyl group contains 18 carbons and 1 double bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
16p11.2 proximal deletion syndrome039

Protein Targets (76)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency37.64600.003245.467312,589.2998AID1705; AID2517
Chain A, Beta-lactamaseEscherichia coli K-12Potency50.11870.044717.8581100.0000AID485294
Chain A, Ferritin light chainEquus caballus (horse)Potency17.78285.623417.292931.6228AID2323
Chain A, CruzipainTrypanosoma cruziPotency19.95260.002014.677939.8107AID1476
endonuclease IVEscherichia coliPotency17.78280.707912.432431.6228AID1708
thioredoxin reductaseRattus norvegicus (Norway rat)Potency29.41700.100020.879379.4328AID488773; AID588453; AID588456
phosphopantetheinyl transferaseBacillus subtilisPotency89.12510.141337.9142100.0000AID1490
ATAD5 protein, partialHomo sapiens (human)Potency11.57740.004110.890331.5287AID493107
USP1 protein, partialHomo sapiens (human)Potency44.66840.031637.5844354.8130AID504865
NFKB1 protein, partialHomo sapiens (human)Potency0.11220.02827.055915.8489AID895; AID928
GLS proteinHomo sapiens (human)Potency35.48130.35487.935539.8107AID624146
TDP1 proteinHomo sapiens (human)Potency19.56460.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency32.18410.180013.557439.8107AID1460
thyroid stimulating hormone receptorHomo sapiens (human)Potency22.41130.001318.074339.8107AID926; AID938
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency7.07950.28189.721235.4813AID2326
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency10.59090.001530.607315,848.9004AID1224821
arylsulfatase AHomo sapiens (human)Potency1.06911.069113.955137.9330AID720538
alpha-galactosidaseHomo sapiens (human)Potency50.11874.466818.391635.4813AID1467
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency23.45350.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency19.95260.540617.639296.1227AID2364; AID2528
cytochrome P450 2C19 precursorHomo sapiens (human)Potency19.95260.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency31.62280.00636.904339.8107AID883
D(1A) dopamine receptorHomo sapiens (human)Potency31.62280.02245.944922.3872AID488983
chromobox protein homolog 1Homo sapiens (human)Potency50.11870.006026.168889.1251AID540317
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency35.48130.01789.637444.6684AID588834
DNA polymerase betaHomo sapiens (human)Potency31.62280.022421.010289.1251AID485314
mitogen-activated protein kinase 1Homo sapiens (human)Potency3.98110.039816.784239.8107AID995
flap endonuclease 1Homo sapiens (human)Potency8.43680.133725.412989.1251AID588795
tumor susceptibility gene 101 proteinHomo sapiens (human)Potency19.95260.129810.833132.6090AID493005
DNA polymerase eta isoform 1Homo sapiens (human)Potency44.66840.100028.9256213.3130AID588591
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency15.84890.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency24.03530.004611.374133.4983AID463097; AID624297
DNA polymerase kappa isoform 1Homo sapiens (human)Potency17.65890.031622.3146100.0000AID588579
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency31.62280.031610.279239.8107AID884; AID885
M-phase phosphoprotein 8Homo sapiens (human)Potency63.09570.177824.735279.4328AID488949
lethal factor (plasmid)Bacillus anthracis str. A2012Potency10.00000.020010.786931.6228AID912
lamin isoform A-delta10Homo sapiens (human)Potency11.90470.891312.067628.1838AID1459; AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency31.62280.00638.235039.8107AID883
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Rap guanine nucleotide exchange factor 4Homo sapiens (human)Potency89.12513.981146.7448112.2020AID720708
GABA theta subunitRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Fatty acid-binding protein, liverMus musculus (house mouse)Ki0.04300.02100.34832.0000AID1802031
Cannabinoid receptor 1Rattus norvegicus (Norway rat)Ki10.00000.00020.566510.0000AID49674
Cannabinoid receptor 1Homo sapiens (human)Ki3.32500.00010.50779.6000AID1798961; AID262877; AID353802
Cannabinoid receptor 2 Homo sapiens (human)Ki7.77500.00000.415610.0000AID1798961; AID262878; AID353803
Fatty-acid amide hydrolase 1Rattus norvegicus (Norway rat)Ki10.00000.00060.16192.0000AID262878
Corticotropin-releasing factor receptor 2Homo sapiens (human)Ki10.00000.16800.16800.1680AID353803
Acid ceramidaseHomo sapiens (human)IC50 (µMol)500.00000.02070.49251.0000AID1707268
Transient receptor potential cation channel subfamily V member 2Rattus norvegicus (Norway rat)IC50 (µMol)3.60000.03701.93458.6000AID1400243; AID1400244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ReninHomo sapiens (human)EC50 (µMol)0.18500.00330.24340.5420AID660302
Cytochrome P450 3A4Homo sapiens (human)EC50 (µMol)0.18500.00010.23283.2000AID660302
Cytochrome P450 2C8Homo sapiens (human)EC50 (µMol)0.18500.18500.36350.5420AID660302
Cannabinoid receptor 1Mus musculus (house mouse)EC50 (µMol)0.18500.15850.28110.5420AID660302
Cannabinoid receptor 2Mus musculus (house mouse)EC50 (µMol)0.18500.00730.15460.7040AID660302
Peroxisome proliferator-activated receptor deltaHomo sapiens (human)EC50 (µMol)1.10000.00020.84609.1000AID1630669
Peroxisome proliferator-activated receptor alphaHomo sapiens (human)EC50 (µMol)0.14380.00061.607410.0000AID1239206; AID1630670; AID275787; AID660301; AID660302
Glucose-dependent insulinotropic receptorMus musculus (house mouse)EC50 (µMol)2.90002.90002.90002.9000AID1301392
Transient receptor potential cation channel subfamily V member 1Homo sapiens (human)EC50 (µMol)2.05750.00051.06746.3096AID1798962; AID262881; AID353804; AID725619
Glucose-dependent insulinotropic receptorHomo sapiens (human)EC50 (µMol)2.30430.00071.61865.1300AID1329812; AID1399464; AID1450123; AID1656759; AID725615; AID727514; AID736013
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
FATTY-ACID-CoA LIGASE FADD28 (FATTY-ACID-CoA SYNTHETASE) (FATTY-ACID-CoA SYNTHASE)Mycobacterium tuberculosis H37RvAC50100.00002.730045.826498.7200AID624273
heat shock protein HSP 90-alpha isoform 2Homo sapiens (human)AC507.66600.19503.667918.6960AID540270
heat shock protein 90, putativePlasmodium falciparum 3D7AC509.25000.19504.992098.5000AID540268
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (207)

Processvia Protein(s)Taxonomy
kidney developmentReninHomo sapiens (human)
mesonephros developmentReninHomo sapiens (human)
angiotensin maturationReninHomo sapiens (human)
renin-angiotensin regulation of aldosterone productionReninHomo sapiens (human)
proteolysisReninHomo sapiens (human)
regulation of blood pressureReninHomo sapiens (human)
male gonad developmentReninHomo sapiens (human)
hormone-mediated signaling pathwayReninHomo sapiens (human)
response to lipopolysaccharideReninHomo sapiens (human)
response to immobilization stressReninHomo sapiens (human)
drinking behaviorReninHomo sapiens (human)
regulation of MAPK cascadeReninHomo sapiens (human)
cell maturationReninHomo sapiens (human)
amyloid-beta metabolic processReninHomo sapiens (human)
response to cAMPReninHomo sapiens (human)
response to cGMPReninHomo sapiens (human)
cellular response to xenobiotic stimulusReninHomo sapiens (human)
juxtaglomerular apparatus developmentReninHomo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
lipid hydroxylationCytochrome P450 2C8Homo sapiens (human)
organic acid metabolic processCytochrome P450 2C8Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C8Homo sapiens (human)
steroid metabolic processCytochrome P450 2C8Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C8Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C8Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C8Homo sapiens (human)
retinol metabolic processCytochrome P450 2C8Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 2C8Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C8Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C8Homo sapiens (human)
oxidative demethylationCytochrome P450 2C8Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C8Homo sapiens (human)
positive regulation of acute inflammatory response to antigenic stimulusCannabinoid receptor 1Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerCannabinoid receptor 1Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayCannabinoid receptor 1Homo sapiens (human)
spermatogenesisCannabinoid receptor 1Homo sapiens (human)
axonal fasciculationCannabinoid receptor 1Homo sapiens (human)
response to nutrientCannabinoid receptor 1Homo sapiens (human)
memoryCannabinoid receptor 1Homo sapiens (human)
positive regulation of neuron projection developmentCannabinoid receptor 1Homo sapiens (human)
negative regulation of serotonin secretionCannabinoid receptor 1Homo sapiens (human)
positive regulation of fever generationCannabinoid receptor 1Homo sapiens (human)
negative regulation of fatty acid beta-oxidationCannabinoid receptor 1Homo sapiens (human)
regulation of synaptic transmission, GABAergicCannabinoid receptor 1Homo sapiens (human)
response to lipopolysaccharideCannabinoid receptor 1Homo sapiens (human)
negative regulation of mast cell activationCannabinoid receptor 1Homo sapiens (human)
negative regulation of dopamine secretionCannabinoid receptor 1Homo sapiens (human)
response to nicotineCannabinoid receptor 1Homo sapiens (human)
cannabinoid signaling pathwayCannabinoid receptor 1Homo sapiens (human)
response to cocaineCannabinoid receptor 1Homo sapiens (human)
glucose homeostasisCannabinoid receptor 1Homo sapiens (human)
positive regulation of apoptotic processCannabinoid receptor 1Homo sapiens (human)
response to ethanolCannabinoid receptor 1Homo sapiens (human)
negative regulation of action potentialCannabinoid receptor 1Homo sapiens (human)
negative regulation of blood pressureCannabinoid receptor 1Homo sapiens (human)
positive regulation of blood pressureCannabinoid receptor 1Homo sapiens (human)
regulation of insulin secretionCannabinoid receptor 1Homo sapiens (human)
regulation of synaptic transmission, glutamatergicCannabinoid receptor 1Homo sapiens (human)
maternal process involved in female pregnancyCannabinoid receptor 1Homo sapiens (human)
regulation of feeding behaviorCannabinoid receptor 1Homo sapiens (human)
regulation of penile erectionCannabinoid receptor 1Homo sapiens (human)
retrograde trans-synaptic signaling by endocannabinoidCannabinoid receptor 1Homo sapiens (human)
regulation of presynaptic cytosolic calcium ion concentrationCannabinoid receptor 1Homo sapiens (human)
trans-synaptic signaling by endocannabinoid, modulating synaptic transmissionCannabinoid receptor 1Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayCannabinoid receptor 1Homo sapiens (human)
regulation of metabolic processCannabinoid receptor 1Homo sapiens (human)
response to amphetamineCannabinoid receptor 2 Homo sapiens (human)
inflammatory responseCannabinoid receptor 2 Homo sapiens (human)
immune responseCannabinoid receptor 2 Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerCannabinoid receptor 2 Homo sapiens (human)
leukocyte chemotaxisCannabinoid receptor 2 Homo sapiens (human)
negative regulation of synaptic transmission, GABAergicCannabinoid receptor 2 Homo sapiens (human)
response to lipopolysaccharideCannabinoid receptor 2 Homo sapiens (human)
negative regulation of mast cell activationCannabinoid receptor 2 Homo sapiens (human)
cannabinoid signaling pathwayCannabinoid receptor 2 Homo sapiens (human)
negative regulation of action potentialCannabinoid receptor 2 Homo sapiens (human)
regulation of metabolic processCannabinoid receptor 2 Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayCannabinoid receptor 2 Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
glucose metabolic processPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
generation of precursor metabolites and energyPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
lipid metabolic processPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
fatty acid beta-oxidationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
apoptotic processPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
embryo implantationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
cholesterol metabolic processPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
cell population proliferationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
axon ensheathmentPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
fatty acid catabolic processPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of gene expressionPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
regulation of skeletal muscle satellite cell proliferationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
fatty acid transportPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
intracellular receptor signaling pathwayPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
cell-substrate adhesionPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
cellular response to nutrient levelsPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
wound healingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
steroid hormone mediated signaling pathwayPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of skeletal muscle tissue regenerationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
keratinocyte proliferationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of fat cell differentiationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
negative regulation of myoblast differentiationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
negative regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
decidualizationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
negative regulation of epithelial cell proliferationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
keratinocyte migrationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
adipose tissue developmentPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
fat cell proliferationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of fat cell proliferationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
cellular response to hypoxiaPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
energy homeostasisPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
apoptotic signaling pathwayPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
glucose transmembrane transportPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of myoblast proliferationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
fatty acid metabolic processPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
negative regulation of cholesterol storagePeroxisome proliferator-activated receptor deltaHomo sapiens (human)
cell differentiationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
negative regulation of inflammatory responsePeroxisome proliferator-activated receptor deltaHomo sapiens (human)
hormone-mediated signaling pathwayPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
negative regulation of cytokine production involved in inflammatory responsePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of reactive oxygen species biosynthetic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of hepatocyte apoptotic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of signaling receptor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of ATP biosynthetic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of transformation of host cell by virusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to hypoxiaPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
gluconeogenesisPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
heart developmentPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to nutrientPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
epidermis developmentPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cellular response to starvationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of cellular ketone metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of macrophage derived foam cell differentiationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of cholesterol storagePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of sequestering of triglyceridePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
intracellular receptor signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of fatty acid beta-oxidationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of appetitePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to insulinPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
circadian regulation of gene expressionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
behavioral response to nicotinePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
wound healingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
lipoprotein metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of circadian rhythmPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
steroid hormone mediated signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to ethanolPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of gluconeogenesisPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of blood pressurePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of glycolytic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nitric oxide metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of fatty acid oxidationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of lipid biosynthetic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of inflammatory responsePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of cell growth involved in cardiac muscle cell developmentPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
enamel mineralizationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cellular response to fructose stimulusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of leukocyte cell-cell adhesionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of fatty acid transportPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
hormone-mediated signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
fatty acid metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cell differentiationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cell surface receptor signaling pathwayCorticotropin-releasing factor receptor 2Homo sapiens (human)
cellular response to corticotropin-releasing hormone stimulusCorticotropin-releasing factor receptor 2Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayCorticotropin-releasing factor receptor 2Homo sapiens (human)
long-term synaptic potentiationCorticotropin-releasing factor receptor 2Homo sapiens (human)
fatty acid metabolic processAcid ceramidaseHomo sapiens (human)
keratinocyte differentiationAcid ceramidaseHomo sapiens (human)
sphingosine biosynthetic processAcid ceramidaseHomo sapiens (human)
ceramide biosynthetic processAcid ceramidaseHomo sapiens (human)
ceramide catabolic processAcid ceramidaseHomo sapiens (human)
regulation of steroid biosynthetic processAcid ceramidaseHomo sapiens (human)
regulation of programmed necrotic cell deathAcid ceramidaseHomo sapiens (human)
cellular response to tumor necrosis factorAcid ceramidaseHomo sapiens (human)
thermoceptionTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IITransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
fever generationTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
microglial cell activationTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
diet induced thermogenesisTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
peptide secretionTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
negative regulation of systemic arterial blood pressureTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
lipid metabolic processTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
cell surface receptor signaling pathwayTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
chemosensory behaviorTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
negative regulation of heart rateTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
negative regulation of mitochondrial membrane potentialTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
glutamate secretionTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
calcium-mediated signalingTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
cellular response to heatTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
positive regulation of apoptotic processTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
response to peptide hormoneTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
positive regulation of nitric oxide biosynthetic processTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
behavioral response to painTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
sensory perception of mechanical stimulusTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
detection of temperature stimulus involved in thermoceptionTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
detection of temperature stimulus involved in sensory perception of painTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of painTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
protein homotetramerizationTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
excitatory postsynaptic potentialTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
smooth muscle contraction involved in micturitionTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
calcium ion transmembrane transportTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
cellular response to alkaloidTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
cellular response to ATPTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
cellular response to tumor necrosis factorTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
cellular response to acidic pHTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
cellular response to temperature stimulusTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
negative regulation of establishment of blood-brain barrierTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
calcium ion import across plasma membraneTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
response to capsazepineTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
cellular response to nerve growth factor stimulusTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
insulin secretionGlucose-dependent insulinotropic receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayGlucose-dependent insulinotropic receptorHomo sapiens (human)
regulation of metabolic processGlucose-dependent insulinotropic receptorHomo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 4Homo sapiens (human)
G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
calcium-ion regulated exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
positive regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of synaptic vesicle cycleRap guanine nucleotide exchange factor 4Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (82)

Processvia Protein(s)Taxonomy
aspartic-type endopeptidase activityReninHomo sapiens (human)
signaling receptor bindingReninHomo sapiens (human)
insulin-like growth factor receptor bindingReninHomo sapiens (human)
protein bindingReninHomo sapiens (human)
peptidase activityReninHomo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
monooxygenase activityCytochrome P450 2C8Homo sapiens (human)
iron ion bindingCytochrome P450 2C8Homo sapiens (human)
protein bindingCytochrome P450 2C8Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C8Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 2C8Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C8Homo sapiens (human)
aromatase activityCytochrome P450 2C8Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 2C8Homo sapiens (human)
heme bindingCytochrome P450 2C8Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C8Homo sapiens (human)
cannabinoid receptor activityCannabinoid receptor 1Homo sapiens (human)
protein bindingCannabinoid receptor 1Homo sapiens (human)
identical protein bindingCannabinoid receptor 1Homo sapiens (human)
G protein-coupled receptor activityCannabinoid receptor 1Homo sapiens (human)
protein bindingCannabinoid receptor 2 Homo sapiens (human)
cannabinoid receptor activityCannabinoid receptor 2 Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
transcription coactivator bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
DNA bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
DNA-binding transcription factor activityPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
nuclear steroid receptor activityPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
nuclear receptor activityPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
protein bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
zinc ion bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
lipid bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
linoleic acid bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
sequence-specific double-stranded DNA bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription activator activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
transcription coactivator bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription factor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nuclear steroid receptor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nuclear receptor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
zinc ion bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
lipid bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
phosphatase bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein domain specific bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
mitogen-activated protein kinase kinase kinase bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
ubiquitin conjugating enzyme bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
sequence-specific DNA bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein-containing complex bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
NFAT protein bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
MDM2/MDM4 family protein bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein bindingCorticotropin-releasing factor receptor 2Homo sapiens (human)
peptide hormone bindingCorticotropin-releasing factor receptor 2Homo sapiens (human)
corticotrophin-releasing factor receptor activityCorticotropin-releasing factor receptor 2Homo sapiens (human)
G protein-coupled peptide receptor activityCorticotropin-releasing factor receptor 2Homo sapiens (human)
corticotropin-releasing hormone receptor activityCorticotropin-releasing factor receptor 2Homo sapiens (human)
protein bindingAcid ceramidaseHomo sapiens (human)
hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in linear amidesAcid ceramidaseHomo sapiens (human)
N-acylsphingosine amidohydrolase activityAcid ceramidaseHomo sapiens (human)
fatty acid amide hydrolase activityAcid ceramidaseHomo sapiens (human)
ceramidase activityAcid ceramidaseHomo sapiens (human)
transmembrane signaling receptor activityTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
extracellular ligand-gated monoatomic ion channel activityTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activityTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
voltage-gated calcium channel activityTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
calcium channel activityTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
protein bindingTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
calmodulin bindingTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
ATP bindingTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
intracellularly gated calcium channel activityTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
chloride channel regulator activityTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
phosphatidylinositol bindingTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
identical protein bindingTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
metal ion bindingTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
phosphoprotein bindingTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
temperature-gated ion channel activityTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
protein bindingGlucose-dependent insulinotropic receptorHomo sapiens (human)
G protein-coupled receptor activityGlucose-dependent insulinotropic receptorHomo sapiens (human)
phosphatidylcholine bindingGlucose-dependent insulinotropic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein-macromolecule adaptor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
small GTPase bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (36)

Processvia Protein(s)Taxonomy
extracellular regionReninHomo sapiens (human)
extracellular spaceReninHomo sapiens (human)
plasma membraneReninHomo sapiens (human)
apical part of cellReninHomo sapiens (human)
extracellular spaceReninHomo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C8Homo sapiens (human)
plasma membraneCytochrome P450 2C8Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C8Homo sapiens (human)
cytoplasmCytochrome P450 2C8Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C8Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
mitochondrial outer membraneCannabinoid receptor 1Homo sapiens (human)
plasma membraneCannabinoid receptor 1Homo sapiens (human)
actin cytoskeletonCannabinoid receptor 1Homo sapiens (human)
growth coneCannabinoid receptor 1Homo sapiens (human)
presynaptic membraneCannabinoid receptor 1Homo sapiens (human)
membrane raftCannabinoid receptor 1Homo sapiens (human)
glutamatergic synapseCannabinoid receptor 1Homo sapiens (human)
GABA-ergic synapseCannabinoid receptor 1Homo sapiens (human)
plasma membraneCannabinoid receptor 1Homo sapiens (human)
cytoplasmCannabinoid receptor 1Homo sapiens (human)
plasma membraneCannabinoid receptor 2 Homo sapiens (human)
dendriteCannabinoid receptor 2 Homo sapiens (human)
extrinsic component of cytoplasmic side of plasma membraneCannabinoid receptor 2 Homo sapiens (human)
perikaryonCannabinoid receptor 2 Homo sapiens (human)
endoplasmic reticulumCannabinoid receptor 2 Homo sapiens (human)
plasma membraneCannabinoid receptor 2 Homo sapiens (human)
cytoplasmCannabinoid receptor 2 Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
nucleusPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
nucleusPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
nucleoplasmPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
chromatinPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
nucleusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nucleoplasmPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
chromatinPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nucleusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
plasma membraneCorticotropin-releasing factor receptor 2Homo sapiens (human)
axon terminusCorticotropin-releasing factor receptor 2Homo sapiens (human)
plasma membraneCorticotropin-releasing factor receptor 2Homo sapiens (human)
dendriteCorticotropin-releasing factor receptor 2Homo sapiens (human)
early endosomeAcid ceramidaseHomo sapiens (human)
endoplasmic reticulumAcid ceramidaseHomo sapiens (human)
extracellular regionAcid ceramidaseHomo sapiens (human)
extracellular spaceAcid ceramidaseHomo sapiens (human)
nucleusAcid ceramidaseHomo sapiens (human)
lysosomeAcid ceramidaseHomo sapiens (human)
lysosomal lumenAcid ceramidaseHomo sapiens (human)
extracellular exosomeAcid ceramidaseHomo sapiens (human)
tertiary granule lumenAcid ceramidaseHomo sapiens (human)
ficolin-1-rich granule lumenAcid ceramidaseHomo sapiens (human)
plasma membraneTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
external side of plasma membraneTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
membraneTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
dendritic spine membraneTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
neuronal cell bodyTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
postsynaptic membraneTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
plasma membraneTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
receptor complexGlucose-dependent insulinotropic receptorHomo sapiens (human)
plasma membraneGlucose-dependent insulinotropic receptorHomo sapiens (human)
cytoplasmGlucose-dependent insulinotropic receptorHomo sapiens (human)
cytosolRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (135)

Assay IDTitleYearJournalArticle
AID1345261Human GPR119 (GPR18, GPR55 and GPR119)2013Journal of biomolecular screening, Jun, Volume: 18, Issue:5
Screening β-arrestin recruitment for the identification of natural ligands for orphan G-protein-coupled receptors.
AID1346733Human Peroxisome proliferator-activated receptor-alpha (1C. Peroxisome proliferator-activated receptors)2005Neuropharmacology, Jun, Volume: 48, Issue:8
Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats.
AID1345070Human GPR55 (GPR18, GPR55 and GPR119)2007British journal of pharmacology, Dec, Volume: 152, Issue:7
The orphan receptor GPR55 is a novel cannabinoid receptor.
AID1345261Human GPR119 (GPR18, GPR55 and GPR119)2010Molecular endocrinology (Baltimore, Md.), Jan, Volume: 24, Issue:1
N-oleoyldopamine enhances glucose homeostasis through the activation of GPR119.
AID1346733Human Peroxisome proliferator-activated receptor-alpha (1C. Peroxisome proliferator-activated receptors)2003Nature, Sep-04, Volume: 425, Issue:6953
Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha.
AID1345261Human GPR119 (GPR18, GPR55 and GPR119)2006Cell metabolism, Mar, Volume: 3, Issue:3
Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID100386Evaluated for its growth enhancement or mitogenic activity using LNCaP prostate cultures.2000Bioorganic & medicinal chemistry letters, Sep-04, Volume: 10, Issue:17
5-HETE congeners as modulators of cell proliferation.
AID1450124Agonist activity at human GPR119 expressed in HEK293 cells assessed as increase in cAMP stimulation measured after 60 mins by TR-FRET assay relative to oleoylethanolamide2017Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11
Synthesis and biological evaluation of pyrimidine derivatives with diverse azabicyclic ether/amine as novel GPR119 agonist.
AID459883Inhibition of ceramidase in human SKOV3 cells assessed as hydrolysis of N-((2S,3R)-1,3-dihydroxy-5-((2-oxo-2H-chromen-7- yl)oxy)pentan-2-yl)palmitamide at 16 uM after 24 hrs at 37 degC by HPLC2010Bioorganic & medicinal chemistry, Feb, Volume: 18, Issue:3
Improved synthesis of a fluorogenic ceramidase substrate.
AID459884Inhibition of ceramidase in human SKOV3 cells assessed as hydrolysis of N-((2S,3R)-1,3-dihydroxy-5-((2-oxo-2H-chromen-7- yl)oxy)pentan-2-yl)palmitamide at 16 uM after 24 hrs at 37 degC by umbelliferone formation based fluorescence intensity assay2010Bioorganic & medicinal chemistry, Feb, Volume: 18, Issue:3
Improved synthesis of a fluorogenic ceramidase substrate.
AID1238063Agonist activity at Gal4-tagged human PPARalpha expressed in HEK293 cells at 3 to 30 uM incubated for 16 to 20 hrs by luciferase and beta-galactosidase activity based reporter gene assay2015Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16
Design and synthesis of silicon-containing fatty acid amide derivatives as novel peroxisome proliferator-activated receptor (PPAR) agonists.
AID1189982Antiproliferative activity against human OVCAR3 cells assessed as tumor growth inhibition after 48 hrs by sulforhodamine B assay2015Bioorganic & medicinal chemistry, Jan-15, Volume: 23, Issue:2
Antiproliferative activity of synthetic fatty acid amides from renewable resources.
AID1239206Agonist activity at human PPARalpha transfected in human MCF7 cells after 16 hrs by luciferase reporter gene assay2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Novel Oxazolidinone-Based Peroxisome Proliferator Activated Receptor Agonists: Molecular Modeling, Synthesis, and Biological Evaluation.
AID736013Agonist activity at human GPR119 expressed in HEK293 cells assessed as cAMP accumulation after 60 mins2013Bioorganic & medicinal chemistry, Mar-01, Volume: 21, Issue:5
Synthesis and biological evaluation of novel 2,4-disubstituted quinazoline analogues as GPR119 agonists.
AID38685Tested for hydrolysis by rat brain microsomal anandamide amidohydrolase (AAH).1999Journal of medicinal chemistry, Mar-11, Volume: 42, Issue:5
Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase.
AID1189976Antiproliferative activity against human U251 cells assessed as tumor growth inhibition after 48 hrs by sulforhodamine B assay2015Bioorganic & medicinal chemistry, Jan-15, Volume: 23, Issue:2
Antiproliferative activity of synthetic fatty acid amides from renewable resources.
AID1189977Antiproliferative activity against human MCF7 cells assessed as tumor growth inhibition after 48 hrs by sulforhodamine B assay2015Bioorganic & medicinal chemistry, Jan-15, Volume: 23, Issue:2
Antiproliferative activity of synthetic fatty acid amides from renewable resources.
AID574405Antiinflammatory activity against IFN-gamma-stimulated human HaCaT cells assessed as inhibition of chemokine MDC production at 50 to 100 uM after 18 hrs by ELISA2011Bioorganic & medicinal chemistry, Feb-15, Volume: 19, Issue:4
Evaluation of endogenous fatty acid amides and their synthetic analogues as potential anti-inflammatory leads.
AID1189980Antiproliferative activity against human NCI-H460 cells assessed as tumor growth inhibition after 48 hrs by sulforhodamine B assay2015Bioorganic & medicinal chemistry, Jan-15, Volume: 23, Issue:2
Antiproliferative activity of synthetic fatty acid amides from renewable resources.
AID725620Antiobesity activity in Sabra mouse assessed as reduction in body weight at 1 mg/kg, ip administered on day 0, 10, 11, 12, 24, 29 measured on day 39 relative to control2013Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
Novel acylethanolamide derivatives that modulate body weight through enhancement of hypothalamic pro-opiomelanocortin (POMC) and/or decreased neuropeptide Y (NPY).
AID727513Agonist activity at human GPR119 transfected in HEK293 cells assessed as cAMP stimulation relative to maximal effect of oleylethanolamine2013Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
Synthesis and biological evaluation of 5-nitropyrimidine analogs with azabicyclic substituents as GPR119 agonists.
AID387967Antiproliferative activity against human WI38 cells at 10 uM after 48 hrs relative to control2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
Acylamido analogs of endocannabinoids selectively inhibit cancer cell proliferation.
AID725623Antiobesity activity in Sabra mouse assessed as reduction in body weight at 1 mg/kg, ip administered on day 0, 10, 11, 12, 24, 29 measured on day 33 relative to control2013Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
Novel acylethanolamide derivatives that modulate body weight through enhancement of hypothalamic pro-opiomelanocortin (POMC) and/or decreased neuropeptide Y (NPY).
AID49659Binding affinity towards cannabinoid receptor 1 from rat forebrain membranes in the presence of phenylmethanesulfonylfluoride (PMSF) using 0.8 nM [3H]CP-55940 as radioligand1998Journal of medicinal chemistry, Dec-31, Volume: 41, Issue:27
Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability.
AID1656759Agonist activity at GPR119 (unknown origin) assessed as increase in cAMP level by cAMP HTRF assay2020Bioorganic & medicinal chemistry letters, 02-15, Volume: 30, Issue:4
Design and biological evaluation of tetrahydropyridine derivatives as novel human GPR119 agonists.
AID727514Agonist activity at human GPR119 transfected in HEK293 cells assessed as concentration for 50 % cAMP stimulation of oleylethanolamine2013Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
Synthesis and biological evaluation of 5-nitropyrimidine analogs with azabicyclic substituents as GPR119 agonists.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID459885Inhibition of rat liver ceramidase assessed as hydrolysis of N-((2S,3R)-1,3-dihydroxy-5-((2-oxo-2H-chromen-7- yl)oxy)pentan-2-yl)palmitamide2010Bioorganic & medicinal chemistry, Feb, Volume: 18, Issue:3
Improved synthesis of a fluorogenic ceramidase substrate.
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1400244Antagonist activity at recombinant rat TRPV2 expressed in HEK293 cells assessed as inhibition of CBD-induced Ca2+ levels preincubated for 5 mins followed by agonist addition by Fuo-4-AM based spectrofluorimetry2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
Elongation of the Hydrophobic Chain as a Molecular Switch: Discovery of Capsaicin Derivatives and Endogenous Lipids as Potent Transient Receptor Potential Vanilloid Channel 2 Antagonists.
AID353803Displacement of [3H]CP-55940 from human recombinant CB2 receptor expressed in HEK293 cell membrane2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes.
AID524795Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1630669Transactivation of human Gal4 fused PPARdelta LBD transfected in human HeLa cells after 7 hrs by dual-luciferase reporter gene assay2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Structure-activity relationship studies of non-carboxylic acid peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonists.
AID1329812Agonist activity at human GPR119 expressed in HEK293 cells assessed as stimulation of cAMP level measured after 60 mins by HTRF assay2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Novel 5-nitropyrimidine derivatives bearing endo-azabicyclic alcohols/amines as potent GPR119 agonists.
AID725621Antiobesity activity in Sabra mouse assessed as reduction in body weight at 1 mg/kg, ip administered on day 0, 10, 11, 12, 24, 29 measured on day 36 relative to control2013Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
Novel acylethanolamide derivatives that modulate body weight through enhancement of hypothalamic pro-opiomelanocortin (POMC) and/or decreased neuropeptide Y (NPY).
AID1189972Antiproliferative activity against human PC3 cells after 48 hrs by sulforhodamine B assay2015Bioorganic & medicinal chemistry, Jan-15, Volume: 23, Issue:2
Antiproliferative activity of synthetic fatty acid amides from renewable resources.
AID660302Agonist activity at human PPARalpha expressed in MCF7 cells co-transfected CPTI DR1-type RE after 6 hrs by luciferase reporter gene assay2011ACS medicinal chemistry letters, Nov-10, Volume: 2, Issue:11
Discovery of Potent Dual PPARα Agonists/CB1 Ligands.
AID1630670Transactivation of human Gal4 fused PPARalpha LBD transfected in human HeLa cells after 7 hrs by dual-luciferase reporter gene assay2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Structure-activity relationship studies of non-carboxylic acid peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonists.
AID49674Tested for binding affinity to Cannabinoid receptor 11999Journal of medicinal chemistry, Mar-11, Volume: 42, Issue:5
Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase.
AID196758Tested for inhibition of rat glial cell gap junction at the concentration of 20 uM1999Bioorganic & medicinal chemistry letters, Apr-19, Volume: 9, Issue:8
Arachidonic acid amide inhibitors of gap junction cell-cell communication.
AID275787Activation of human PPARalpha by GST pull down assay2007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
Novel sulfamide analogs of oleoylethanolamide showing in vivo satiety inducing actions and PPARalpha activation.
AID1189978Antiproliferative activity against human NCI/ADR-RES cells assessed as tumor growth inhibition after 48 hrs by sulforhodamine B assay2015Bioorganic & medicinal chemistry, Jan-15, Volume: 23, Issue:2
Antiproliferative activity of synthetic fatty acid amides from renewable resources.
AID524792Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID262878Binding affinity to human recombinant CB2 receptor expressed in COS cells2006Journal of medicinal chemistry, Apr-06, Volume: 49, Issue:7
Oxyhomologues of anandamide and related endolipids: chemoselective synthesis and biological activity.
AID1189968Antiproliferative activity against human MCF7 cells after 48 hrs by sulforhodamine B assay2015Bioorganic & medicinal chemistry, Jan-15, Volume: 23, Issue:2
Antiproliferative activity of synthetic fatty acid amides from renewable resources.
AID1616997Antiallergic activity in rat RBL2H3 cells assessed as inhibition of DNP-HSA-mediated degranulation by measuring decrease in beta-hexosaminidase activity preincubated for 30 mins followed by DNP-HSA stimulation and measured after 30 mins by 4-nitrophenyl 22019Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21
Structure-Activity Relationships of Fish Oil Derivatives with Antiallergic Activity in Vitro and in Vivo.
AID501578Antitubercular activity against Mycobacterium tuberculosis H37Rv after 7 days by resazurin microtiter assay2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Synthesis and antituberculosis activity of new fatty acid amides.
AID262881Agonist activity on human recombinant TRPV1-mediated enhancement of intracellular calcium concentration in HEK293 cells2006Journal of medicinal chemistry, Apr-06, Volume: 49, Issue:7
Oxyhomologues of anandamide and related endolipids: chemoselective synthesis and biological activity.
AID1189969Antiproliferative activity against human NCI/ADR-RES cells after 48 hrs by sulforhodamine B assay2015Bioorganic & medicinal chemistry, Jan-15, Volume: 23, Issue:2
Antiproliferative activity of synthetic fatty acid amides from renewable resources.
AID1189973Antiproliferative activity against human OVCAR3 cells after 48 hrs by sulforhodamine B assay2015Bioorganic & medicinal chemistry, Jan-15, Volume: 23, Issue:2
Antiproliferative activity of synthetic fatty acid amides from renewable resources.
AID387968Antiproliferative activity against mouse RAW264.7 cells at 10 uM after 48 hrs relative to control2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
Acylamido analogs of endocannabinoids selectively inhibit cancer cell proliferation.
AID1656758Agonist activity at GPR119 (unknown origin) assessed as increase in cAMP level at 10 uM by cAMP HTRF assay relative to oleoylethanolamide2020Bioorganic & medicinal chemistry letters, 02-15, Volume: 30, Issue:4
Design and biological evaluation of tetrahydropyridine derivatives as novel human GPR119 agonists.
AID1450123Agonist activity at human GPR119 expressed in HEK293 cells assessed as increase in cAMP stimulation measured after 60 mins by TR-FRET assay2017Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11
Synthesis and biological evaluation of pyrimidine derivatives with diverse azabicyclic ether/amine as novel GPR119 agonist.
AID1301392Agonist activity at mouse GPR119 receptor cotransformed in Saccharomyces cerevisiae cells after 4 hrs by fluorescent Fus1p-LacZ reporter gene assay2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
G Protein-Coupled Receptor 119 (GPR119) Agonists for the Treatment of Diabetes: Recent Progress and Prevailing Challenges.
AID1189979Antiproliferative activity against human 786-0 cells assessed as tumor growth inhibition after 48 hrs by sulforhodamine B assay2015Bioorganic & medicinal chemistry, Jan-15, Volume: 23, Issue:2
Antiproliferative activity of synthetic fatty acid amides from renewable resources.
AID574406Cytotoxicity against human HaCaT cells at 50 to 100 uM after 24 hrs by MTT assay2011Bioorganic & medicinal chemistry, Feb-15, Volume: 19, Issue:4
Evaluation of endogenous fatty acid amides and their synthetic analogues as potential anti-inflammatory leads.
AID725627Antiobesity activity in Sabra mouse assessed as reduction in body weight at 1 mg/kg, ip administered on day 0, 10, 11, 12, 24, 29 measured on day 19 relative to control2013Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
Novel acylethanolamide derivatives that modulate body weight through enhancement of hypothalamic pro-opiomelanocortin (POMC) and/or decreased neuropeptide Y (NPY).
AID262877Binding affinity to human recombinant CB1 receptor expressed in COS cells2006Journal of medicinal chemistry, Apr-06, Volume: 49, Issue:7
Oxyhomologues of anandamide and related endolipids: chemoselective synthesis and biological activity.
AID1707268Inhibition of human acid ceramidase2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Design, Synthesis, and Biological Evaluation of a Series of Oxazolone Carboxamides as a Novel Class of Acid Ceramidase Inhibitors.
AID38682Tested for hydrolysis by rat brain microsomal anandamide amidohydrolase (AAH).1999Journal of medicinal chemistry, Mar-11, Volume: 42, Issue:5
Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase.
AID524793Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID501579Antitubercular activity against rifampicin-resistant Mycobacterium tuberculosis H37Rv ATCC 35338 after 7 days by resazurin microtiter assay2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Synthesis and antituberculosis activity of new fatty acid amides.
AID262880Inhibition of AEA uptake in RBL2H3 cells2006Journal of medicinal chemistry, Apr-06, Volume: 49, Issue:7
Oxyhomologues of anandamide and related endolipids: chemoselective synthesis and biological activity.
AID725615Agonist activity at recombinant GPR119 receptor (unknown origin)2013Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
Novel acylethanolamide derivatives that modulate body weight through enhancement of hypothalamic pro-opiomelanocortin (POMC) and/or decreased neuropeptide Y (NPY).
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID262882Maximal agonist activity on human recombinant TRPV1-mediated enhancement of intracellular calcium concentration in HEK293 cells at 10 uM2006Journal of medicinal chemistry, Apr-06, Volume: 49, Issue:7
Oxyhomologues of anandamide and related endolipids: chemoselective synthesis and biological activity.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID49854Binding affinity towards Cannabinoid receptor 2 from mouse spleen membranes using 0.8 nM [3H]CP-55940 as radioligand1998Journal of medicinal chemistry, Dec-31, Volume: 41, Issue:27
Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability.
AID1399464Agonist activity at GPR119 (unknown origin)
AID1189971Antiproliferative activity against human NCI-H460 cells after 48 hrs by sulforhodamine B assay2015Bioorganic & medicinal chemistry, Jan-15, Volume: 23, Issue:2
Antiproliferative activity of synthetic fatty acid amides from renewable resources.
AID353804Agonist activity at human recombinant TRPV1 expressed in HEK293 cells assessed as increase in intracellular calcium level2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes.
AID262879Metabolic stability in rat brain membrane assessed by inhibition of AEA hydrolysis2006Journal of medicinal chemistry, Apr-06, Volume: 49, Issue:7
Oxyhomologues of anandamide and related endolipids: chemoselective synthesis and biological activity.
AID1189974Cytotoxicity against human HaCaT cells after 48 hrs by sulforhodamine B assay2015Bioorganic & medicinal chemistry, Jan-15, Volume: 23, Issue:2
Antiproliferative activity of synthetic fatty acid amides from renewable resources.
AID725622Antiobesity activity in Sabra mouse assessed as reduction in body weight at 1 mg/kg, ip administered on day 0, 10, 11, 12, 24, 29 measured on day 29 relative to control2013Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
Novel acylethanolamide derivatives that modulate body weight through enhancement of hypothalamic pro-opiomelanocortin (POMC) and/or decreased neuropeptide Y (NPY).
AID275788Agonist activity at human PPARalpha expressed in MCF7 cells transfected with co-activator TIF2 by luciferase reporter gene assay at 1 uM2007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
Novel sulfamide analogs of oleoylethanolamide showing in vivo satiety inducing actions and PPARalpha activation.
AID1189981Antiproliferative activity against human PC3 cells assessed as tumor growth inhibition after 48 hrs by sulforhodamine B assay2015Bioorganic & medicinal chemistry, Jan-15, Volume: 23, Issue:2
Antiproliferative activity of synthetic fatty acid amides from renewable resources.
AID725619Agonist activity at TRPV1 receptor (unknown origin)2013Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
Novel acylethanolamide derivatives that modulate body weight through enhancement of hypothalamic pro-opiomelanocortin (POMC) and/or decreased neuropeptide Y (NPY).
AID196759Inhibition of rat glial cell gap junction at the concentration of 50 uM1999Bioorganic & medicinal chemistry letters, Apr-19, Volume: 9, Issue:8
Arachidonic acid amide inhibitors of gap junction cell-cell communication.
AID725625Antiobesity activity in Sabra mouse assessed as reduction in body weight at 1 mg/kg, ip administered on day 0, 10, 11, 12, 24, 29 measured on day 24 relative to control2013Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
Novel acylethanolamide derivatives that modulate body weight through enhancement of hypothalamic pro-opiomelanocortin (POMC) and/or decreased neuropeptide Y (NPY).
AID1189983Cytotoxicity against human HaCaT cells assessed as tumor growth inhibition after 48 hrs by sulforhodamine B assay2015Bioorganic & medicinal chemistry, Jan-15, Volume: 23, Issue:2
Antiproliferative activity of synthetic fatty acid amides from renewable resources.
AID459886Inhibition of pig liver ceramidase assessed as hydrolysis of N-((2S,3R)-1,3-dihydroxy-5-((2-oxo-2H-chromen-7- yl)oxy)pentan-2-yl)palmitamide2010Bioorganic & medicinal chemistry, Feb, Volume: 18, Issue:3
Improved synthesis of a fluorogenic ceramidase substrate.
AID1189970Antiproliferative activity against human 786-0 cells after 48 hrs by sulforhodamine B assay2015Bioorganic & medicinal chemistry, Jan-15, Volume: 23, Issue:2
Antiproliferative activity of synthetic fatty acid amides from renewable resources.
AID1400243Antagonist activity at recombinant rat TRPV2 expressed in HEK293 cells assessed as inhibition of LPC-induced Ca2+ levels preincubated for 5 mins followed by agonist addition by Fuo-4-AM based spectrofluorimetry2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
Elongation of the Hydrophobic Chain as a Molecular Switch: Discovery of Capsaicin Derivatives and Endogenous Lipids as Potent Transient Receptor Potential Vanilloid Channel 2 Antagonists.
AID725628Antiobesity activity in Sabra mouse assessed as reduction in body weight at 1 mg/kg, ip administered on day 0, 10, 11, 12, 24, 29 measured on day 12 relative to control2013Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
Novel acylethanolamide derivatives that modulate body weight through enhancement of hypothalamic pro-opiomelanocortin (POMC) and/or decreased neuropeptide Y (NPY).
AID725626Antiobesity activity in Sabra mouse assessed as reduction in body weight at 1 mg/kg, ip administered on day 0, 10, 11, 12, 24, 29 measured on day 22 relative to control2013Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
Novel acylethanolamide derivatives that modulate body weight through enhancement of hypothalamic pro-opiomelanocortin (POMC) and/or decreased neuropeptide Y (NPY).
AID736692Inhibition of acid ceramidase (unknown origin)2013Journal of medicinal chemistry, May-09, Volume: 56, Issue:9
Discovery of a new class of highly potent inhibitors of acid ceramidase: synthesis and structure-activity relationship (SAR).
AID1189967Antiproliferative activity against human U251 cells after 48 hrs by sulforhodamine B assay2015Bioorganic & medicinal chemistry, Jan-15, Volume: 23, Issue:2
Antiproliferative activity of synthetic fatty acid amides from renewable resources.
AID725624Antiobesity activity in Sabra mouse assessed as reduction in body weight at 1 mg/kg, ip administered on day 0, 10, 11, 12, 24, 29 measured on day 26 relative to control2013Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
Novel acylethanolamide derivatives that modulate body weight through enhancement of hypothalamic pro-opiomelanocortin (POMC) and/or decreased neuropeptide Y (NPY).
AID49658Binding affinity towards cannabinoid receptor 1 from rat forebrain membranes in the absence of phenylmethanesulfonylfluoride (PMSF) using 0.8 nM [3H]CP-55940 as radioligand1998Journal of medicinal chemistry, Dec-31, Volume: 41, Issue:27
Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability.
AID353802Displacement of [3H]CP-55940 from human recombinant CB1 receptor expressed in HEK293 cell membrane2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes.
AID501580Antitubercular activity against isoniazid-resistant Mycobacterium tuberculosis H37Rv ATCC 35822 after 7 days by resazurin microtiter assay2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Synthesis and antituberculosis activity of new fatty acid amides.
AID660301Agonist activity at human PPARalpha expressed in MCF7 cells co-transfected CPTI DR1-type RE after 16 hrs by luciferase reporter gene assay2011ACS medicinal chemistry letters, Nov-10, Volume: 2, Issue:11
Discovery of Potent Dual PPARα Agonists/CB1 Ligands.
AID1508591NCATS Rat Liver Microsome Stability Profiling2020Scientific reports, 11-26, Volume: 10, Issue:1
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
AID1508612NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Highly predictive and interpretable models for PAMPA permeability.
AID1645848NCATS Kinetic Aqueous Solubility Profiling2019Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1798961CB Receptor Radioligand Binding Assay (Ki) from Article 10.1021/jm900130m: \\Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes.\\2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes.
AID1802031FABP1 Fluorescent Ligand Displacement Assay from Article 10.1021/acs.biochem.6b00446: \\FABP1: A Novel Hepatic Endocannabinoid and Cannabinoid Binding Protein.\\2016Biochemistry, 09-20, Volume: 55, Issue:37
FABP1: A Novel Hepatic Endocannabinoid and Cannabinoid Binding Protein.
AID1798962TRPV1 Channel Activity Assay from Article 10.1021/jm900130m: \\Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes.\\2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (434)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (0.69)18.7374
1990's15 (3.46)18.2507
2000's108 (24.88)29.6817
2010's242 (55.76)24.3611
2020's66 (15.21)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 47.39

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index47.39 (24.57)
Research Supply Index6.12 (2.92)
Research Growth Index5.66 (4.65)
Search Engine Demand Index72.65 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (47.39)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials17 (3.90%)5.53%
Reviews31 (7.11%)6.00%
Case Studies1 (0.23%)4.05%
Observational1 (0.23%)0.25%
Other386 (88.53%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]